Sufentanil Citrate/Ketamine Hydrochloride

Published: 16. October, 2024 Cessatech announces that recruitment has today reached the halfway point for patient recruitment with… Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202 75 paediatric patients have now been recruited in Study 0202 • Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in children CT001 is a nasal spray for the treatment of acute pain in children Link to full release Jes Trygved, CEO, Cessatech We are very pleased with this halfway milestone in our final study for the development of CT001 in paediatric patients. We had a slow start during the summer holiday period, but since beginning of September all sites are up and running and we have recruited more than 30 patients, this is a fantastic achievement and great effort by the team – and a potentially good indication that the product is well accepted among the involved sites. CT001 is now one step closer to finalize the clinical program and becoming available to hospitals and the children that really need approved, easy to administer pain relief.”

Published: 12. August, 2024 Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the… Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001 The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S has been increased from DKK 5 million to DKK 10 million and the maturity extended until April 2026. The new loan facility agreement provides Cessatech increased financial flexibility and support for the upcoming US launch of CT001. To date Cessatech has not drawn on the facility and the Loan Facility Agreement can potentially be converted into shares on market conditions. Jes Trygved, CEO Cessatech “The extended loan facility gives us more financial flexibility during the next 18-24 months for the upcoming launch US launch and operations as we still expect to begin generating revenues in 2024. We are very pleased that the group of investors providing the loan facility supports Cessatech and our work to bring solutions to the unmet medical need of treating children who are experiencing acute pain. In addition, it is important to Cessatech that the Loan Facility Agreement may be converted into shares.” Link to Release